New stocks news | Zytpeptide Biologics has submitted an application to the Hong Kong Stock Exchange. Zweigru Peptide is expected to become the world's first approved monthly dosing GLP-1 RA peptide therapy to be listed on the market.

According to the disclosure of the Hong Kong Stock Exchange on April 24, 2026, Beijing Peptide Biopharmaceutical Technology Co., Ltd. (Peptide Biopharmaceutical) has submitted an application for listing to the Hong Kong Stock Exchange, with joint sponsors including Rothschild and Huatai International. Company Profile Peptide Biopharmaceutical was established in 2018 and is a biopharmaceutical company nearing the commercialization stage. It has built a diversified product portfolio covering monthly injectables, oral peptide therapy, and multi-target therapy to meet the increasingly personalized treatment needs of the global obesity and other metabolic disease populations. To meet the differentiated needs of different patient groups, the company has established a diversified product portfolio consisting of eight investigational drugs covering three major treatment modalities, aiming to provide differentiated clinical characteristics and patient experience: (a) monthly injectables, aiming to reduce dosing frequency from once a week to once a month; (b) oral peptide formulations, aiming to achieve safety and efficacy comparable to injectables in a convenient tablet form; and (c) multi-target therapy, simultaneously acting on GLP-1 and other synergistic metabolic pathways (such as Fibroblast Growth Factor 21 (FGF21) and Amylin), to address complications and more severe conditions in patient populations. This product portfolio structure ensures that each candidate drug can target specific clinical scenarios and patient populations, providing doctors and patients with a broader range of treatment options covering efficacy, tolerability, convenience, and affordability. The development status of four clinical-stage candidate drugs and four preclinical-stage candidate drugs is as follows: The core product Zovigreglupide is a phase III clinical-stage monthly GLP-1 receptor agonist for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease. It has the potential to become the world's first marketed and best-in-class monthly GLP-1 receptor agonist peptide injectable. The monthly dosing regimen of Zovigreglupide benefits from the company's QLLong platform's di-fatty acid chain conjugation technology, which increases its binding affinity to albumin by about nine times compared to exenatide, extending its terminal half-life to about 12 days (exenatide is about 5 days). The company completed its first patient enrolment in China's phase III clinical trial for the treatment of obesity in January 2026. According to industry consulting data, as of the last feasible date, calculated based on the time of entry into phase III clinical trials, Zovigreglupide leads most competitors in China by about four to five years. Financial Information Revenue: In the fiscal years 2024 and 2025, the company achieved revenues of approximately 4.01 million yuan and 3.13 million yuan, respectively. Loss: In the fiscal years 2024 and 2025, the company incurred losses of approximately 164 million yuan and 191 million yuan, respectively. Year-end cash and cash equivalents At the end of the fiscal years 2024 and 2025, the year-end cash and cash equivalents were approximately 351 million yuan and 312 million yuan, respectively. Industry Overview In recent years, the global obesity/overweight drug market has achieved rapid growth, driven primarily by factors such as increasing prevalence of obesity/overweight, recognition of obesity/overweight as a chronic disease requiring drug intervention, and the emergence of highly effective drug treatment options. GLP-1 receptor agonists have become the dominant category of drugs in this market, contributing the majority of revenue from obesity/overweight drugs and fundamentally reshaping the industry's competitive landscape. The global market size increased from approximately $2.4 billion in 2020 to approximately $18.6 billion in 2024, with a compound annual growth rate of approximately 67.3% over four years. By 2035, the global market is expected to reach approximately $80.6 billion, with a compound annual growth rate of approximately 14.3% from 2024 to 2035. The Chinese market has particularly significant growth potential. The Chinese market is expected to increase from approximately $300 million in 2024 to about $12.7 billion in 2035, primarily driven by the expansion of GLP-1 receptor agonist therapy; during the same period, the GLP-1 receptor agonist market in China is expected to increase from approximately $100 million to about $10.7 billion. In recent years, the global prevalence of metabolic dysfunction-associated fatty liver disease has steadily increased and is expected to continue to grow alongside the increasing prevalence of obesity/overweight, type 2 diabetes, and other metabolic risk factors. The global number of people with metabolic dysfunction-associated fatty liver disease increased from approximately 276.6 million in 2020 to approximately 302 million in 2024 and is expected to reach 380.4 million by 2035. In China, the number of people with metabolic dysfunction-associated fatty liver disease increased from approximately 38.2 million in 2020 to about 42.6 million in 2024 and is expected to reach approximately 56.3 million by 2035. With the approval and market entry of the first batch of specialized therapies for metabolic dysfunction-associated fatty liver disease, the market for drugs for metabolic dysfunction-associated fatty liver disease is in its early but rapidly developing commercialization stage. The global market size for drugs for metabolic dysfunction-associated fatty liver disease was approximately $3 billion in 2024 and is expected to reach approximately $90.9 billion by 2035; in China, the market for drugs for metabolic dysfunction-associated fatty liver disease is expected to reach about $8.8 billion by 2035. Board of Directors Information The board of directors consists of 11 directors, including 5 executive directors, 2 non-executive directors, and 4 independent non-executive directors. The directors serve a term of 3 years and are eligible for re-election. Equity Structure Dr. Zhang, Dr. Zhang Yuanyuan, Dr. Zhai, Mr. Wu, and Tianjin Peptide each hold approximately 11.88%, 1.58%, 1.58%, 1.58%, and 9.08% of the company's issued share capital, respectively. Dr. Zhang, Dr. Zhang Yuanyuan, Dr. Zhai, and Mr. Wu (collectively referred to as the "concerted actors") have signed a concerted action agreement, and Tianjin Peptide has not entered into any commitment or agreement with the concerted actors. However, as Dr. Zhang is a general partner of Tianjin Peptide and has the right to exercise voting rights, Tianjin Peptide should be considered a concerted actor. Therefore, as of the last feasible date, Dr. Zhang, Mr. Wu, Dr. Zhang Yuanyuan, Dr. Zhai, and Tianjin Peptide collectively have the right to exercise approximately 25.72% of the company's voting rights and constitute a single largest shareholder group of the company. HSG Venture is a wholly-owned subsidiary of HongShan Capital Venture Fund VII, L.P. HongShan Capital Venture Fund VII, L.P. is managed by HSG Venture VII Management, L.P., and HSG Venture VII Management, L.P. is managed by HSG Holding Limited. HSG Holding Limited is fully owned by SNP China Enterprises Limited, and SNP China Enterprises Limited is fully owned by Mr. Shen Nanpeng. Lan Chi (Chongqi) Small and Medium-sized Enterprise Development Private Equity Investment Fund Partnership Enterprise (Limited Partnership) ("Lan Chi Small and Medium-sized Enterprise") is a limited partnership established under Chinese law. The general partner of Lan Chi Small and Medium-sized Enterprise is Suzhou Lan Chi Newze Venture Investment Partnership Enterprise (Limited Partnership) ("Suzhou Lan Chi Newze"), whose general partner is Suzhou Lan Chi New Cheng Venture Investment Limited Liability Company, ultimately controlled by Mr. Zhu Tianyu. According to the Securities and Futures Ordinance, Mr. Zhu is deemed to have an interest in the shares held by Lan Chi Small and Medium-sized Enterprise, Hangzhou Lan Chi New Han, Lan Chi New Yue, and Jiaxing Chi Yue. OrbiMed Asia Partners IV, L.P. is the sole shareholder of OrbAmed Asia IV (Hong Kong) Limited. OrbiMed Asia Partners V, L.P. is the sole shareholder of OrbAmed Asia V (Hong Kong) Limited. OrbiMed Advisors LLC is the advisor to OrbiMed Asia Partners IV, L.P. and OrbiMed Asia Partners V, L.P. Therefore, according to the Securities and Futures Ordinance, OrbiMed Advisors LLC is deemed to have an interest in the shares held by OrbiMed Asia IV and OrbiMed Asia V. Beijing Noubo Te Biotech Co., Ltd. is fully owned by Imeik Technology Development Co., Ltd. ("Imeik Technology Development"), a company listed on the Shenzhen Stock Exchange (300896.SZ). Therefore, according to the Securities and Futures Ordinance, Imeik Technology Development is deemed to have an interest in the shares held by Beijing Noubo Te. Shenyang Jiahong No. 1 Low Carbon Venture Investment Partnership Enterprise (Limited Partnership) ("Shenyang Jiahong No. 1") is a limited partnership established under Chinese law. The general partner of Shenyang Jiahong No. 1 is China-US Green Fund Management Co., Ltd. ("China-US Green Fund"), a limited liability company ultimately controlled by Mr. Xu Lin. As of the last feasible date, the sole limited partner holding 30% or more of the partnership interests in Shenyang Jiahong No. 1 is China-US Green Equity Investment Fund (Limited Partnership) ("China-US Green Tong"). Therefore, according to the Securities and Futures Ordinance, China-US Green Fund, China-US Green Tong, and Mr. Xu Lin are deemed to have an interest in the shares held by Shenyang Jiahong No. 1. Hangzhou Qiming Rongjing Equity Investment Partnership Enterprise (Limited Partnership) ("Hangzhou Qiming Rongjing") is a limited partnership established under Chinese law. The general partner of Hangzhou Qiming Rongjing is Suzhou Qikun Venture Investment Partnership Enterprise (Limited Partnership) ("Suzhou Qikun"). The general partners of Suzhou Qikun are Suzhou Qi Wang Venture Investment Limited Company, with 50% held by Jia and 50% held by Xu Jing. The limited partner of Suzhou Qikun is Suzhou Qiyuan Equity Investment Management Partnership No. 1, with 99.33% of the partnership interests. As of the last feasible date, no limited partner holds 30% or more of the partnership interests in Hangzhou Qiming Rongjing. Therefore, according to the Securities and Futures Ordinance, Suzhou Qikun, Suzhou Qi Wang, Suzhou Qiyuan, Jia, and Xu Jing are deemed to have an interest in the shares held by Hangzhou Qiming Rongjing. Suzhou Xingze Xingyong Emerging Medical Industry Investment Fund Management Partnership Enterprise (Limited Partnership) ("Suzhou Xingze Xingyong") is a limited partnership established under Chinese law. The general partner of Suzhou Xingze Xingyong is Suzhou Xingze Equity Investment Center (Limited Partnership) ("Suzhou Xingze Equity"). The general partner of Suzhou Xingze Equity is Shanghai Xingze Investment Management Co., Ltd. ("Shanghai Xingze"), controlled by Mr. Liu Wenyi. Therefore, according to the Securities and Futures Ordinance, Suzhou Xingze Equity, Shanghai Xingze, and Liu Wenyi are deemed to have an interest in the shares held by Suzhou Xingze Xingyong. Intermediary Team Joint Sponsors: Rothschild Financial Group Hong Kong Limited, Huatai Financial Holdings (Hong Kong) Limited Legal Advisor to the Company: Hong Kong and U.S. Law: King & Wood Mallesons Hong Kong; Chinese Law: Beijing Junhe Law Firm Legal Advisor to the Joint Sponsors: Hong Kong and Law: Latham & Watkins in association with Beijing Tiancheng Law Firm; Chinese Law: Tiancheng Law Firm Reporting Accountant and Auditor: Ernst & Young LLP Industry Consultant: Zhaoshi Industry Consulting Co., Ltd.